35 Recruiting Advanced Lymphoma Clinical Trials

Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.

📍 Find Near Me by Distance

Browse by State

Alabama Maryland Pennsylvania

Browse by Study Phase

Phase2: 32 studies Phase1: 1 study

Top Interventions for Advanced Lymphoma

Crizotinib (5)Trametinib Dimethyl Sulfoxide (4)Palbociclib (3)PI3K-beta Inhibitor GSK2636771 (3)Sapanisertib (3)Ulixertinib (2)Vismodegib (2)Copanlisib Hydrochloride (2)

Related Conditions

Advanced Malignant Solid Neoplasm (33)Refractory Malignant Solid Neoplasm (33)Refractory Lymphoma (32)Refractory Multiple Myeloma (30)Hematopoietic and Lymphoid Cell Neoplasm (18)Hematopoietic and Lymphatic System Neoplasm (2)Recurrent Malignant Solid Neoplasm (2)

Top Recruiting Advanced Lymphoma Studies

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Palbociclib (PD-0332991) as Potentially Targeting Treatment in Cancers With CDK4 or CDK6 Amplification (MATCH - Subprotocol Z1C)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Genetic Changes (MATCH - Subprotocol C1)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Crizotinib as Potentially Targeted Treatment in Cancers With MET Exon 14 Deletion Genetic Changes (MATCH - Subprotocol C2)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Trametinib as a Potential Targeted Treatment in Cancers With GNAQ or GNA11 Genetic Changes (MATCH-Subprotocol S2)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing GDC-0449 (Vismodegib) as Potentially Targeted Treatment in Cancers With Smoothened or Patched 1 Mutant Tumors (MATCH - Subprotocol T)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Copanlisib as a Potential Targeted Treatment in Cancers With PIK3CA Mutations (MATCH-Subprotocol Z1F)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

📍 University of Alabama at Birmingham Cancer Center — Birmingham, Alabama

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing JNJ-42756493 (Erdafitinib) as Potentially Targeting Treatment in Cancers With FGFR Amplifications (MATCH-Subprotocol K1)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing AZD5363 as a Potential Targeted Treatment in Cancers With AKT Genetic Changes (MATCH-Subprotocol Y)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing AZD1775 as a Potential Targeted Treatment in Cancers With BRCA Genetic Changes (MATCH-Subprotocol Z1I)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Expression (MATCH - Subprotocol Z1H)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing GDC-0032 (Taselisib) as a Potential Targeted Treatment in Cancers With PIK3CA Genetic Changes (MATCH-Subprotocol I)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing LOXO-101 as Potentially Targeted Treatment in Cancers With NTRK Genetic Changes (MATCH - Subprotocol Z1E)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing VS-6063 (Defactinib) as a Potential Targeted Treatment in Cancers With NF2 Genetic Changes (MATCH-Subprotocol U)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic

Testing Ado-Trastuzumab Emtansine as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol Q)

📍 ECOG-ACRIN Cancer Research Group — Philadelphia, Pennsylvania

View Study & Checklist ➔

🟢 Recruiting Phase1 💊 Investigational Drug / Biologic

Studying TAK-243 in Patients With Advanced Cancer

📍 National Cancer Institute Developmental Therapeutics Clinic — Bethesda, Maryland

View Study & Checklist ➔